US FDA clears Interventional Spine’s lordotic Opticage


The US Food and Drug Administration has cleared Interventional Spine’s 80 lumbar lordotic Opticage expandable intervertebral body fusion device

The lordotic 80 Opticage is a lumbar intervertebral body fusion device and is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1.

The new lordotic 80 Opticage is designed to help correct the pressure on the lower spine, potentially alleviating the pain that patients experience as a result of lordosis. The new Opticage can be implanted via posterior, transforaminal or lateral approach.  In addition, the Lordotic 80 Opticage is designed to provide for optimum graft injection through its patented delivery system.

Interventional Spine is currently in the process of assessing other sizes and configurations for its line of Lordotic Expandable Opticages, according to a company release.